Clinical Study on the EBV CAR-T /TCR-T Cells in the Treatment of Nasopharyngeal Carcinoma
Status:
Not yet recruiting
Trial end date:
2030-10-01
Target enrollment:
Participant gender:
Summary
This study was a single-arm, open-label, "3 + 3" dose-escalation Exploratory research. The
patients were divided into two groups: EBV TCR-T-cell Group and EBV CAR-T-cell group. The EBV
CAR-T-treated group received three progressively increasing dose levels (3.0 × 106 cells/kg,
9.0 × 106 cells/kg, 1.5 × 107 cells/kg) of EBV GP350 CAR-T-cell therapy; The EBV TCR-T-cell
group received three progressively increasing doses (5.0 × 106 cells/kg, 1.5 × 107 cells/kg,
3.0 × 107 cells/kg) of EBV LMP2A TCR-T-cell therapy.